Governance · TSX-V: ZEN · Nasdaq: ZTEK
Five directors. Elected at the Annual and Special Meeting of Shareholders, September 25, 2025.
The Board
Zentek's Board pairs deep scientific and commercial pharmaceutical experience with expertise in finance, critical minerals, and international development.
Chairman of the Board · B.Sc., MBA · Audit Committee · Corporate Governance, Compensation & Nominating Committee
Mr. Snisarenko is a senior executive with 35 years of specialty pharmaceutical, biologics, medical device and commercialisation experience spanning from start-up to large pharma and biotech companies. He served as Group Vice-President and Head of Ophthalmology Franchise for Shire/Takeda, and as Chief Commercial Officer of Oyster Point Pharma. He is currently an Independent Director and Board Member of Alimera Sciences and Cytophage Technologies Ltd. Mr. Snisarenko holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University.
Chief Executive Officer & Director
Mr. Jiwan is the Chief Executive Officer and a member of the Board of Directors of Zentek Ltd. He brings extensive experience in corporate strategy, capital markets, and critical minerals development. Mr. Jiwan has been instrumental in repositioning Zentek toward a technology-focused graphite processing business targeting nuclear, defence, semiconductor, and advanced battery end markets. He holds deep expertise in public company governance, investor relations, and strategic finance.
Director · Board Secretary · CPA · Audit Committee Chair · Corporate Governance, Compensation & Nominating Committee Chair
Mr. Wallman has been a Chartered Professional Accountant since 1986. He recently retired from private industry where he held executive positions within the dairy processing and manufacturing sectors. His most recent work involved strategic planning and business unit leadership. He has also served on several industry-related boards.
Independent Director · Audit Committee · Corporate Governance, Compensation & Nominating Committee
Mr. Fontes is a Project Manager and Partner at Catalyst Custom Modular in British Columbia, which specialises in creating innovative, economical custom prefabricated modules utilising modern building science. He has commissioned next-generation HVAC systems on both site-built and modular custom homes. Prior to his role at Catalyst, he was the proprietor of Fontes Homes. Mr. Fontes brings expertise in entrepreneurship, building innovation, and project planning.
Independent Director · Audit Committee · Corporate Governance, Compensation & Nominating Committee
Mr. Gettinby is the former Director of International Development at RSK Environment Limited, a global leader in the delivery of environmental and engineering solutions. He worked at RSK between 2019 and 2025, and prior to his most recent role, he was the Regional Development Director for the Middle East. Prior to RSK, he was Land Manager at Vattenfall in Edinburgh and London. Mr. Gettinby is a renewable energy leader with extensive experience in property, agriculture, land management, and energy sectors across the Middle East, Africa, Asia, and the UK. He has proven expertise in market expansion, client acquisition, and team mentorship.
Independence & Committees
All directors except the CEO are independent within the meaning of applicable Canadian and US securities regulations. The Board has two standing committees: Audit (Chair: Eric Wallman), and Corporate Governance, Compensation & Nominating (Chair: Eric Wallman).
Zentek is a reporting issuer in Canada listed on the TSX Venture Exchange (ZEN) and a foreign private issuer in the United States listed on Nasdaq Capital Market (ZTEK). Continuous disclosure documents are filed on SEDAR+ and EDGAR.